contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


fluoguide-fluoguide-enters-agreement-with-swedish-university-hospital-for-the-second-phase-of-the-ongoing-fg001-clinical-trial-correction

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

FluoGuide

Correction: The subject line in e-mail recipients contained a wrong text. No other corrections. Copenhagen, Denmark, 30 June 2021 - FluoGuide A/S ("FluoGuide" or the "Company") is pleased to...

<div class="abstract">Correction: The subject line in e-mail recipients&nbsp;contained a wrong text. No other corrections.&nbsp; Copenhagen, Denmark, 30 June 2021 - FluoGuide A/S ("FluoGuide" or the "Company") is pleased to announce that the Company has entered into an agreement with the Department of Neurosurgery, Linköping University Hospital, Sweden to become the second site investigating FG001's effect in guiding surgical removal of aggressive brain cancer. Linköping University Hospital is added to the second phase of the ongoing clinical phase I/II trial.&nbsp;</div>The ongoing clinical phase I/II trial with FG001 is designed as a two-phase trial, where the first phase aims to identify the optimal dose and investigate safety and tolerability. The second phase will provide efficacy data that will be used to design the following pivotal phase III trial intended to support regulatory approval of FG001 in high grade glioma, aggressive brain cancer. Several of the design elements needed in the pivotal phase III trial is included in the ongoing clinical phase I/II trial of FG001 for use in guiding surgery of glioblastoma.In collaboration with Copenhagen University Hospital ("Rigshospitalet") in Denmark, FG001 is currently in the first phase of the clinical trial. For the second phase of the clinical trial, Linköping University Hospital will be included to provide diversity to the trial by working with different centers in different counties. Peter Milos (MD) will be the principal investigator at Linköping University Hospital. The Swedish site is expected to start recruiting patients during H2 2021."The neurosurgery department of the University Hospital in Linköping, Sweden is well known for its innovative research in the field of neurosurgery and involvement in numerous clinical trials in brain cancer", says Morten Albrechtsen, CEO and continues "I am also delighted that Peter Milos, who is an experienced and well reputed neurosurgeon, will be the one to lead the trial in Linköping"."There is large need for improving the treatment of patients with high grade glioma and I am looking forward to investigate FG001 in guiding surgery of these patients", says Peter Milos, MD

Fluoguide: FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial (correction)